References
- Ruiter GA, Verheij M, Zerp SF, van Blitterswijk WJ. Alkyl-lysophospholipids as anticancer agents and enhancers of radia-tion-induced apoptosis. Int J Radiat Oncol Biol Phys 2001; 49 (2): 415–419.
- Santa-Rita RM, Henriques-Pons A, Barbosa HS, de Castro SL. Effect of the lysophospholipid analogues edelfosine, ilmofo-sine and miltefosine against Leishmania amazonensis. J An-timicrob Chemother 2004; 54 (4): 704–710.
- Croft SL, Snowdon D, Yardley V. The activities of four an-ticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J Antimicrob Chemother 1996; 38 (6): 1041–1047.
- Nakayama H, Loiseau PM, Bones C, Torres de Ortiz S, Schinini A, Serna E, et al. Efficacy of orally administered 2-sub-stituted quinolines in experimental murine cutaneous and visceral leishmaniasis. Antimicrob Agents Chemother 2005; 49 (12): 4950-4956.
- Widmer F, Wright LC, Obando D, Hanke R, Ganendren R, Ellis DH, et al. Hexadecylphosphocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis. Antimicrob Agents Chemother 2006; 50 (2): 414–421.
- Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, Fisher C, et al. Miltefosine, an oral agent, for the treatment of In-dian visceral leishmaniasis. N Engl J Med 1999; 341 (24): 1795–1800.
- Rosenow C, Ryan P, Weiser JN, Johnson S, Fontan P, Or-tqvist A, et al. Contribution of novel choline-binding proteins to adherence, colonization and immunogenicity of Streptococcus pneumoniae. Mol Microbiol 1997; 25 (5): 819–829.
- Llull D, Rivas L, Garcia E. In vitro bactericidal activity of the antiprotozoal drug miltefosine against Streptococcus pneumo-niae and other pathogenic streptococci. Antimicrob Agents Chemother 2007; 51 (5): 1844–1848.
- Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility test for bacteria that grow aer-obically. Approved standards. 7th ed. Wayne, PA: Clinical and Laboratory Standards Institute, 2006.
- O'Reilly T, Cleeland R, Squires EL. Evaluation of antimi-crobials in experimental animal infections. In: Lorian V, ed. An-tibiotics in laboratory medicine. 4th edition. Baltimore, MD: Williams & Wilkins, 1996: 604–765.
- Huelves L, Sevillano D, Martinez-Mann C, López-Casla MT, Gracia M, Alou L, et al; Spanish Pneumococcal Infection Study Network (G03/103). Correlation between in vitro and in vivo activity of levofloxacin and moxifloxacin against pneumo-coccal strains with different susceptibilities to fluoroquinolones. Int J Antimicrob Agents. 2006; 27 (4): 294–299.
- Breiser A, Kim DJ, Fleer EA, Damenz W, Drube A, Berger M, et al. Distribution and metabolism of hexadecylphospho-choline in mice. Lipids 1987; 22 (11): 925–926.
- Unger C, Reer E, Damenz W, Hilgard P, Nagel G, Eibl U. Hexadecylphosphocholine: determination of serum concentra-tions in rats. J Lipid Mediat 1991; 3 (1): 71–78.
- Marschner N, Kotting J, Eibl H, Unger C. Distribution of hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine in rat tissues during steady-state treatment. Can-cer Chemother Pharmacol 1992; 31 (1): 18–22.